Company / PP&E (Net)
Mirum Pharmaceuticals, Inc. PP&E (Net) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.9M
FY2025
5-year range
$706.0K / $1.9M
FY2021-FY2025
Trend
+63.5%
vs FY2024
Sector context
#138 of 193
Health Care
What the data says
At $2M, Mirum Pharmaceuticals, Inc.'s pp&e (net) ranks #138 of 193 in the Health Care sector. Improved from $706,000 to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +7.6%.
Improved from $706,000 to $2M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +26.8%
- 5-Year CAGR
- +7.6%
- 10-Year CAGR
- -
Sector benchmark
#138 of 193 in Health CareTop 72% of 193This company $1.9M Sector average $777.6M
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.6%, indicating consistent growth.
- In FY2025, pp&e (net) increased 63.5% year-over-year.
- Ranks #138 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -26.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.9M | +63.5% |
| FY2024 | $1.1M | +61.3% |
| FY2023 | $706.0K | -22.8% |
| FY2022 | $914.0K | -6.8% |
| FY2021 | $981.0K | -24.1% |
| FY2020 | $1.3M | -5.8% |
| FY2019 | $1.4M | - |
| FY2018 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026